Update shared on 26 Nov 2025
Fair value Increased 0.83%Narrative Update on Ipca Laboratories
Analysts have raised their price target for Ipca Laboratories from ₹1,529.94 to ₹1,542.56. This change reflects optimism due to improved forecasts for revenue growth and profit margins.
What's in the News
- Ipca Laboratories will hold a Board Meeting on October 17, 2025, at 17:00 Indian Standard Time (Key Developments).
- Another Board Meeting is scheduled for November 13, 2025. The agenda includes considering and recording the Standalone and Consolidated Unaudited Financial Results for the second quarter and half year ended September 30, 2025 (Key Developments).
- Ipca Laboratories and BioSimilar Sciences PR LLC announced a definitive Technology Transfer and Joint Development Agreement. This agreement shifts late-stage development, clinical manufacture, and commercial supply of a next generation anti-cancer and anti-inflammatory monoclonal antibody biosimilar to BioSimilar Sciences PR LLC’s campus in Aguadilla, Puerto Rico (Key Developments).
Valuation Changes
- Consensus Analyst Price Target has risen slightly from ₹1,529.94 to ₹1,542.56.
- Discount Rate remains unchanged at 12.76%.
- Revenue Growth projection has increased slightly from 10.74% to 10.92%.
- Net Profit Margin estimate has risen from 14.03% to 14.50%.
- Future P/E ratio has fallen significantly from 31.92x to 21.98x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.